BALPHARMA vs FDC: Stock Comparison
FDC is the larger company by market capitalisation. FDC shows a higher ROE, a higher dividend yield and faster revenue growth. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
BALPHARMA leads 0; FDC leads 9 of 11
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | BALPHARMA | FDC |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Pharmaceuticals | Pharmaceuticals |
Price
| Metric | BALPHARMA | FDC |
|---|---|---|
| Live Price | ₹106.79 | ₹340.45 |
| Day Change | 0.99% | 0.24% |
| Volume | 25,522 | 2.18 L |
| 52-Week High | ₹124.6 | ₹473.6 |
| 52-Week Low | ₹60 | ₹312.95 |
| Distance from 52W High | -14.29% | -28.11% |
Valuation
| Metric | BALPHARMA | FDC |
|---|---|---|
| Market Cap | ₹134 Cr | ₹5,580 Cr |
| P/E Ratio | — | 19.07x |
| P/B Ratio | — | 2.25x |
| EPS | ₹0.71 | ₹8.14 |
| Book Value | ₹51.66 | ₹152.64 |
| Dividend Yield | 1.36% | 1.47% |
Growth
| Metric | BALPHARMA | FDC |
|---|---|---|
| Revenue Growth (TTM YoY) | 2.7% | 18.9% |
| EPS Growth (TTM YoY) | -33.5% | 166.8% |
| Qtr Sales Growth | 0% | 0% |
| Qtr Profit Growth | 0% | 0% |
Profitability & Leverage
| Metric | BALPHARMA | FDC |
|---|---|---|
| ROE | 6.49% | 11.47% |
| ROCE | 9.07% | 11.8% |
| Net Margin | 2.02% | 12.96% |
| Operating Margin | 7.46% | 18.03% |
| Debt to Equity | 1.48x | 0x |
Shareholding
As of Sep 2026 • change vs previous quarter| Metric | BALPHARMA | FDC |
|---|---|---|
| Promoter Holding | 46.74% | 69.66% |
| FII Holding | 0.28%▲ 0.13 pp | 1.58%▲ 0.18 pp |
| DII Holding | 0% | 6.59%▲ 0.28 pp |
| Public Holding | 48.87%▼ 0.12 pp | 22.17%▼ 0.46 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: BALPHARMA and FDC.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.